Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 9/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094363 | 0.84 | OPRM1 (0.52) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL6476230 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7096004 | 0.82 | OPRM1 (0.50) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7463493 | 0.82 | OPRM1 (0.50) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7093821 | 0.81 | OPRM1 (0.53) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7095042 | 0.81 | OPRM1 (0.53) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7094878 | 0.80 | OPRM1 (0.45) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7095434 | 0.80 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7094475 | 0.80 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRL1OPRD1 | |
| SCHEMBL7095112 | 0.80 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102762-B1 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-11-13 | — | — | EP | claimed |
| EP-1102762-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2001-05-30 | — | — | EP | claimed |
| US-6172067-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000008013-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-02-17 | — | — | WO | claimed |
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | ITO FUMITAKA (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1102762-B1 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1102762-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6172067-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000008013-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OPRM1 | OPRM1 3/4885OPRK1 6/4885OGFRL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.